| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b1d08574feb5fc8275d94ffbd43d4cc0 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-375
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-548
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-542
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7052
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-662
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K41-0038 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-375
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7052
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-54 |
| filingDate |
2019-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5cf333b7af978d75be81c7239f848b0e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09957242454d31602134bba948be330a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e5758c47ccc3cf6cce1d98ffe2336fb5 |
| publicationDate |
2021-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20210104829-A |
| titleOfInvention |
Triple Combination Therapy Targets Mitochondria and Kills Cancer Stem Cells |
| abstract |
In some embodiments, cancer stem cells (CSCs) can be eliminated through novel therapeutic strategies using FDA-approved antibiotics and dietary supplements. This approach effectively results in synergistic clearance of CSCs by inhibiting mitochondrial biogenesis in CSCs during induced mitochondrial oxidative stress, without inhibiting normal cells. Embodiments may include therapeutic agents that inhibit mitochondrial biogenesis and target large mitochondrial ribosomes, therapeutic agents that inhibit mitochondrial biogenesis and target small mitochondrial ribosomes, and therapeutic agents that act as pro-oxidants or induce mitochondrial oxidative stress. Compositions according to this approach inhibited CSC proliferation by about 90% in the MCF7 ER(+) cell line during a preliminary study, confirming a reduction in mitochondrial oxygen consumption and ATP production. Some embodiments minimize the problem of antibiotic resistance by including an antibiotic concentration below the antimicrobial antibiotic concentration. In some embodiments, one or more therapeutic agents are conjugated to a targeting signal. |
| priorityDate |
2018-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |